[SCHEDULE 13G] Nasus Pharma Ltd. SEC Filing

Rhea-AI Filing Summary

Capital Point Ltd. reported ownership of 575,129 ordinary shares of Nasus Pharma Ltd., representing 6.35% of the outstanding class based on 9,059,635 shares. The filing shows Capital Point has sole voting and dispositive power over those shares and indicates the holdings were not acquired to change or influence control of the issuer. The report identifies the filer as an Israel-organized entity and provides principal office addresses for both the issuer and filer. The statement is a Schedule 13G disclosure of beneficial ownership and does not include transactions, financial results, or forward-looking commentary.

Positive

• Material disclosure of a >5% beneficial ownership (575,129 shares, 6.35%) providing transparency to the market
• Sole voting and dispositive power is clearly stated, reducing ambiguity about how the stake is controlled
• Filer attests the position is not held to change or influence control, consistent with Schedule 13G treatment

Negative

• None.

Insights

Financial Analyst

TL;DR A passive investor disclosed a >5% stake with sole voting and dispositive power, which may attract market attention but contains no transaction detail.

Capital Point's 6.35% stake is material in size for a single holder and must be tracked by shareholders and analysts because stakes above 5% can influence shareholder dynamics or future proposals, even if the filer attests no intent to change control. The filing lacks dates of acquisition and any schedule of purchases, so its impact on recent trading or cost basis is unclear. Monitor for any subsequent Schedule 13D or Form 4 filings that would indicate activist intent or trading activity.

Corporate Governance Expert

TL;DR Disclosure shows centralized control over the shares but affirms passive purpose; governance implications depend on future filings or engagement.

Holding sole voting and dispositive power over a >5% block gives Capital Point the ability to vote substantially, which can matter for corporate actions. However, the certification states the shares are not held to influence control and the filer used Schedule 13G, consistent with a passive investor profile. From a governance perspective, absence of group affiliations, nominee arrangements, or shared power reduces immediate governance risk; still, board and management should note the holder and be prepared for potential engagement.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Nasus Pharma Ltd.

(Name of Issuer)

Ordinary Shares, no par value

(Title of Class of Securities)

M7071P109

(CUSIP Number)

08/14/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. M7071P109

1

Names of Reporting Persons

Capital Point Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

ISRAEL

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 575,129.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 575,129.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

575,129.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.35 %

12

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: With regard to Rows (5), (7) and (9), please see Item 4. Row (11) is based on 9,059,635 ordinary shares issued and outstanding as of August 13, 2025 (as provided by the Issuer).

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Nasus Pharma Ltd.
(b)	Address of issuer's principal executive offices: Yigal Alon 65, Tel Aviv, Israel, 6744317
Item 2.
(a)	Name of person filing: Capital Point Ltd.
(b)	Address or principal business office or, if none, residence: Azrieli 1, Tel Aviv 67021, Israel
(c)	Citizenship: Israel
(d)	Title of class of securities: Ordinary Shares, no par value
(e)	CUSIP No.: M7071P109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See Row 9 of cover page of the reporting person. .
(b)	Percent of class: See Row 11 of cover page of the reporting person.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Row 5 of cover page of the reporting person.
	(ii) Shared power to vote or to direct the vote: See Row 6 of cover page of the reporting person.
	(iii) Sole power to dispose or to direct the disposition of: See Row 7 of cover page of the reporting person.
	(iv) Shared power to dispose or to direct the disposition of: See Row 8 of cover page of the reporting person.
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Capital Point Ltd.

Signature:	/s/ Avi Katzav
Name/Title:	Chief Financial Officer
Date:	08/20/2025

Signature:	/s/ Yossi Tamar
Name/Title:	Co-Chief Executive Officer
Date:	08/20/2025

FAQ

What stake in Nasus Pharma (NSRX) does Capital Point Ltd. report?

Capital Point Ltd. reports beneficial ownership of 575,129 ordinary shares, representing 6.35% of the class based on 9,059,635 shares outstanding.

Does Capital Point have voting control over the reported shares?

Yes. The filing states Capital Point has sole voting power and sole dispositive power over the 575,129 shares.

Was the stake reported as acquired to influence control of Nasus Pharma?

No. The certification states the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer.

What form was filed and why is it used?

A Schedule 13G was filed; it is used by persons who own more than 5% and assert a passive investment purpose rather than an intent to influence control.

Where is the filer organized and where are principal offices?

Capital Point Ltd. is organized in Israel; the issuer's principal executive office is listed at Yigal Alon 65, Tel Aviv, Israel.